Tradestie Institutional Equity Comparison Engine
MYGN vs VCYT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
VCYT Overall Edge
VCYT Captures Institutional Edge (2โ2 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Veracyte, Inc. (VCYT) driven by superior Valuation, Growth & Margin while MYGN counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, MYGN trades at 54.0x Forward P/E with -13.3% operating margin (-1.5% YoY revenue) versus VCYT at 15.3x Forward P/E and 15.0% operating margin (+15.1% YoY). In options structure, MYGN sits in SURGE (22nd %ile IV; Dealer Gamma Walls on Pro) against VCYT sits in BREAKDOWN (47th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
VCYT
MYGN 54.0x vs VCYT 15.3x Fwd P/E
Growth & Margin Winner
VCYT
Op Margin -13.3% vs 15.0% ยท YoY -1.5% vs +15.1%
Momentum & Technical Winner
MYGN
1Y -12.3% vs -39.8% ยท 52W Pos 53% vs 5%
Options & Structure Winner
MYGN
SURGE (22nd %ile IV) vs BREAKDOWN (47th %ile IV)
MYGN
NASDAQ
Myriad Genetics Inc
In Vitro & In Vivo Diagnostic Substances
$5.57
-1.59% 1D
Market Cap
$542.9M
1M Return
+39.95%
1Y Return
-12.28%
Forward P/E
54.0x
Unified AI Score
46.2 / 100
HOLD
Tech 30.0
Fund 43.0
Flow 56.0
Mom 50.0
VCYT
NASDAQ
Veracyte, Inc.
Services-Medical Laboratories
$24.01
-1.32% 1D
Market Cap
$2.0B
1M Return
-44.32%
1Y Return
-39.78%
Forward P/E
15.3x
Unified AI Score
49.1 / 100
HOLD
Tech 55.0
Fund 56.0
Flow 57.0
Mom 55.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
MYGN -12.28%
VCYT -39.78%
Spread: +27.5 pp (MYGN Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MYGN Revenue | VCYT Revenue | MYGN Op. Margin | VCYT Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $740M | $90M | 16.4% | -24.2% | MYGN |
| FY2019 | $850M | $120M | 0.9% | -12.6% | MYGN |
| FY2020 | $560M | $120M | -52.0% | -30.1% | VCYT |
| FY2021 | $690M | $220M | -27.6% | -37.3% | MYGN |
| FY2022 | $680M | $300M | -20.7% | -13.9% | VCYT |
| FY2023 | $750M | $360M | -34.2% | -23.8% | VCYT |
| FY2024 | $840M | $450M | -14.7% | 3.6% | VCYT |
| FY2025 | $820M | $520M | -47.0% | 11.2% | VCYT |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MYGN | VCYT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $542.9M | $2.0B | Larger Scale | VCYT |
| Trailing P/E Ratio Valuation | 54.0x | 15.8x | Lower Multiple | VCYT |
| Forward P/E Ratio Valuation | 54.0x | 15.3x | Lower Multiple | VCYT |
| Revenue Growth (YoY) Growth | -1.5% | +15.1% | Higher Growth | VCYT |
| Operating Margin (TTM) Profitability | -13.3% | 15.0% | Higher Margin | VCYT |
| Net Profit Margin Profitability | -16.1% | 21.8% | Higher Margin | VCYT |
| Return on Equity (ROE) Capital Efficiency | -40.2% | 9.4% | Higher ROE | VCYT |
| 52-Week Range Position Momentum | 53% ($3โ$8) | 5% ($22โ$61) | Stronger Trend | MYGN |
| Beta / 30D Volatility Risk Regime | 0.68ฮฒ ยท 122% Vol | 3.01ฮฒ ยท 199% Vol | Lower Realized Risk | MYGN |
| Unified Institutional Score Composite Signal | 46.2 / 100 (HOLD) | 49.1 / 100 (HOLD) | Higher Composite | VCYT |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full MYGN vs VCYT Buy Guide
MYGN
SURGE
12d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
22nd %ile
IV Regime
Compressed (<25th %ile)
VCYT
BREAKDOWN
99d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
47th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither MYGN nor VCYT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.